for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Alligator Bioscience AB

ATORX.ST

Latest Trade

12.08SEK

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

10.60

 - 

28.45

As of on the Stockholm Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
12.08
Open
--
Volume
--
3M AVG Volume
7.43
Today's High
--
Today's Low
--
52 Week High
28.45
52 Week Low
10.60
Shares Out (MIL)
71.39
Market Cap (MIL)
866.66
Forward P/E
-4.18
Dividend (Yield %)
--

Next Event

Q3 2019 Alligator Bioscience AB Earnings Release

Latest Developments

More

Alligator Bioscience April-June Operating Loss At SEK 50.5 Mln

Alligator Bioscience Q4 Net Sales Fall To SEK 25.6 Million

Alligator Bioscience Will Receive $3.5 Mln Under Agreement With Abclon

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Alligator Bioscience AB

Alligator Bioscience AB is a Sweden-based company that is engaged in development of immunotherapies for the treatment of cancer. The Company specializes in the development of tumor-directed immunotherapies, in particular agonistic mono- and bispecific antibodies. In the discovery of those drugs, the Company uses its technology platforms ALLIGATOR-GOLD and FIND. ALLIGATOR-GOLD is a library containing human antibodies. FIND (which stands for Fragment Induced Diversity) is an antibody optimization technology. In its pipeline, the Company has thee projects: ADC-1013 (antibody), ATOR-1015 (bispecific immune activating antibody) and ATOR-1016 (bispecific agonistic antibody), which are in research/preclinical stage.

Industry

Biotechnology & Drugs

Contact Info

Scheelevagen 2 Byggnad 401

+46.46.2864280

https://alligatorbioscience.se/

Executive Leadership

Peter Arthur Benson

Chairman of the Board

Per Norlen

Chief Executive Officer, Chief Medical Officer

Per-Olof Schrewelius

Chief Financial Officer

Peter Ellmark

Vice President Discovery

Christina Furebring

Vice President Research and Development

Key Stats

1.75 mean rating - 4 analysts
Sell
Hold
Buy
Revenue (MM, SEK)

2016

0.1K

2017

0.1K

2018

0.0K

2019(E)

0.0K
EPS (SEK)

2016

-0.800

2017

-0.890

2018

-2.100

2019(E)

-2.908
Price To Earnings (TTM)
--
Price To Sales (TTM)
33.51
Price To Book (MRQ)
2.31
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
5.15
LT Debt To Equity (MRQ)
3.66
Return on Investment (TTM)
-35.37
Return on Equity (TTM)
-33.25

Latest News

Latest News

BRIEF-Alligator Bioscience Q1 Operating Loss Widens To SEK 44.0 Million

* Q1 OPERATING LOSS SEK 44.0 MILLION VERSUS LOSS SEK 19.1 MILLION YEAR AGO Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Alligator Bioscience AB Oct-Dec Net Sales, SEK 51.3 Million

* OCT-DEC OPERATING RESULT, SEK 10.7 MILLION (-22.1) Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Alligator Bioscience Contracts Theradex Oncology As Clinical CRO

* ALLIGATOR BIOSCIENCE CONTRACTS THERADEX ONCOLOGY AS CLINICAL CRO FOR THE UPCOMING ATOR-1015 PHASE I STUDY

BRIEF-Alligator Bioscience To Receive Milestone Payment From Janssen

* ALLIGATOR BIOSCIENCE TO RECEIVE USD 6 MILLION MILESTONE PAYMENT FROM JANSSEN COUPLED TO THE DECISION TO INITIATE COMBINATION TRIAL WITH ADC-1013

BRIEF-Alligator Bioscience appoints Charlotte A Russell as Chief Medical Officer​

* ALLIGATOR BIOSCIENCE AB - APPOINTMENT OF CHARLOTTE A RUSSELL AS CHIEF MEDICAL OFFICER

BRIEF-Alligator Bioscience ‍Q3 operating loss widens to SEK 24.5 mln​

* Q3 OPERATING LOSS, SEK 24.5 MILLION (LOSS: 9.1) Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Aptevo Therapeutics and Alligator Bioscience announced further details of collaboration on ALG.APV-527​

* Aptevo Therapeutics Inc - co, Alligator Bioscience announced further details of companies' collaboration on ALG.APV-527 Source text for Eikon: Further company coverage:

BRIEF-Alligator Bioscience signs collaboration agreement for 4-1BB

* ALLIGATOR BIOSCIENCE SIGNS IMMUNOTHERAPY RESEARCH COLLABORATION AGREEMENT FOR 4-1BB

BRIEF-Alligator Bioscience Q2 operating loss lowers to SEK 29.5 mln

* Q2 NET SALES SEK 1.3 MILLION VERSUS SEK 3.8 MILLION YEAR AGO

BRIEF-Aptevo and Alligator Bioscience start IND-enabling development activities immunotherapy drug

* Aptevo Therapeutics and Alligator Bioscience commence IND-enabling development activities for new bispecific immunotherapy candidate ALG.APV-527 Source text for Eikon: Further company coverage:

BRIEF-Alligator Bioscience expands collaboration with Stanford University

* EXPANDS IMMUNO-ONCOLOGY COLLABORATION WITH STANFORD UNIVERSITY Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Aptevo Therapeutics and Alligator Bioscience to co-develop novel bispecific antibody

* APTEVO THERAPEUTICS AND ALLIGATOR BIOSCIENCE ANNOUNCE PLANS TO CO-DEVELOP NOVEL BISPECIFIC ANTIBODY FOR TUMOR-DIRECTED IMMUNOTHERAPY

BRIEF-Aptevo Therapeutics and Alligator Bioscience announce plans to co-develop novel bispecific antibody for tumor-directed immunotherapy

* Aptevo Therapeutics and Alligator Bioscience announce plans to co-develop novel bispecific antibody for tumor-directed immunotherapy

BRIEF-Alligator Bioscience advances ATOR-1017 into pre-clinical development​

* ALLIGATOR BIOSCIENCE HAS ADVANCED ANOTHER WHOLLY-OWNED CHECKPOINT MODULATOR PROGRAM, ATOR-1017, INTO PRE-CLINICAL DEVELOPMENT Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Alligator Bioscience Q1 operating result swings to loss SEK 19.1 million

* Q1 NET SALES SEK 2.5 MILLION VERSUS SEK 43.4 MILLION YEAR AGO

BRIEF-Alligator: completion of first phase I study with CD40 agonistic immuno-oncology antibody ADC-1013

* Announces completion of first phase I study with CD40 agonistic immuno-oncology antibody ADC-1013

BRIEF-Alligator Bioscience Q4 operating loss narrows to SEK 22.1 mln

* Q4 net sales 6.4 million Swedish crowns ($725,000) versus 0.5 million crowns year ago

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up